- RecruitingPHASE2
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
This study looks at giving more doses of Lutathera to people with a certain type of gut cancer that has started to grow again. It aims to see if two extra doses are better than just watching the cancer closely.
For: Neuroendocrine Tumors · Intestinal Well Differentiated Endocrine Tumor · Progressive DiseaseFrance - Active not recruiting
Post-Authorization Long-Term Safety Study of LUTATHERA
This study looks at the long-term safety of a treatment called LUTATHERA for a type of cancer called neuroendocrine tumours. Researchers want to understand any side effects that might appear over time in patients who have received this medicine.
For: Neuroendocrine TumorsUnited States · France · Portugal - Active not recruitingPHASE3
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
This study looked at a new treatment called Lutathera for advanced bowel and stomach neuroendocrine tumours (NETs). It compared Lutathera plus standard long-acting octreotide against a higher dose of octreotide alone, to see if it helped patients live longer without their cancer growing.
For: Gastro-enteropancreatic Neuroendocrine TumorUnited States · Canada · France - RecruitingPHASE1
Lutathera and ASTX727 in Neuroendocrine Tumours
This study looks at a new way to treat neuroendocrine tumours. It checks if taking a medicine called ASTX727 before Lutathera helps Lutathera work better. Doctors will use special scans to see if this combination treatment improves how your body responds.
For: Neuroendocrine TumorsUnited Kingdom